The N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma
Shiyan Wang,Yong Zeng,Lin Zhu,Min Zhang,Lei Zhou,Weixiong Yang,Weishan Luo,Lina Wang,Yanming Liu,Helen Zhu,Xin Xu,Peiran Su,Xinyue Zhang,Musaddeque Ahmed,Wei Chen,Moliang Chen,Sujun Chen,Mykhaylo Slobodyanyuk,Zhongpeng Xie,Jiansheng Guan,Wen Zhang,Aafaque A. Khan,Shingo Sakashita,Ni Liu,Nhu-An Pham,Paul C. Boutros,Zunfu Ke,Michael F. Moran,Zongwei Cai,Chao Cheng,Jun Yu,Ming Sound. Tsao,Housheng Hansen. He
DOI: https://doi.org/10.1158/2159-8290.cd-23-1212
IF: 28.2
2024-06-27
Cancer Discovery
Abstract:Comprehensive m6A epitranscriptome profiling of primary tumors remains largely uncharted. Here, we profiled the m6A epitranscriptome of 10 non-neoplastic lung (NL) tissues and 51 lung adenocarcinoma (LUAD) tumors, integrating the corresponding transcriptome, proteome and extensive clinical annotations. We identified distinct clusters and genes that were exclusively linked to disease progression through m6A modifications. In comparison with NL tissues, we identified 430 transcripts to be hypo-methylated and 222 to be hyper-methylated in tumors. Among these genes, EML4 emerged as a novel metastatic driver, displaying significant hyper-methylation in tumors. m6A modification promoted the translation of EML4, leading to its widespread overexpression in primary tumors. Functionally, EML4 modulated cytoskeleton dynamics through interacting with ARPC1A, enhancing lamellipodia formation, cellular motility, local invasion, and metastasis. Clinically, high EML4 protein abundance correlated with features of metastasis. METTL3 small molecule inhibitor markedly diminished both EML4 m6A and protein abundance, and efficiently suppressed lung metastases in vivo.
oncology